After a two-year investigation, a man working for a Chinese conglomerate was arrested on charges of stealing inbred corn seed from production fields in Iowa and Illinois and trying to smuggle it into China, U.S.» Read More
WESTMINSTER, Colo.-- Federal regulators gave the go-ahead to Arca Biopharma to begin human clinical testing of its treatment for atrial fibrillation, the company said Wednesday. Arca believes it has identified genetic variations that predict whether a patient will be helped by treatment with the drug Gencaro.
Dec 3- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.
*Copies of antibody drugs start to hit market in Europe. *Norway plans studies to reassure on safety of switching. But although Europe has pioneered their path to market- approving the first biosimilar drug in 2006 and the latest, an antibody drug from U.S.-based Hospira and Celltrion of South Korea, in September- uptake has been patchy.
*Two or 3 more deals and Compugen could turn a profit. TEL AVIV, Nov 25- Israel's Compugen, which is trying to develop commercial drugs using computer models, says it could turn a profit if it can secure two or three more deals like its recent partnership with Bayer in immuno-oncology.
Nov 22- The U.S. Food and Drug Administration said on Friday it has approved a vaccine made by GlaxoSmithKline Plc for use in the event of an H5N1 bird flu epidemic. The vaccine, Pandemrix, will be added to the national stockpile and will not be available for commercial use, the FDA said.
The encouraging results in the early stage trial from Novavax, a biopharmaceutical company based in Rockville, Maryland, were published online in the New England Journal of Medicine.
*FDA questions drug trial design, says approval application premature. *FDA suggests company may need to do larger trial. Nov 12- Sarepta Therapeutics Inc lost more than 60 percent of its market value after it was advised by the U.S. health regulator to find new ways to test its flagship treatment for a rare muscle disorder.
ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion diagnostics unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for pharmaceutical mergers and acquisitions.
FRANKFURT, Nov 8- Germany's Boehringer Ingelheim, the world's largest unlisted drugmaker, is looking to expand its animal health business and is set to make an offer for poultry vaccine and feed additives maker Lohmann, two people familiar with the matter said.
Nov 5- Keryx Biopharmaceuticals Inc said its sole drug in development, Zerenex, proved to be effective in treating patients with chronic kidney disease who were not on dialysis. Keryx shares jumped 20 percent after the company said Zerenex met the main goal of a mid-stage trial.
*Sales growth in China slows to 5 pct from 15 pct in Q2. PARIS, Oct 30- French drugmaker Sanofi lowered its 2013 profit guidance for a second time after a slowdown in China, weaker generic sales in Brazil and manufacturing problems at a Toronto vaccine plant dented third-quarter results.
RIO DE JANEIRO, Oct 28- Brazils top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.
Sept 23- Alnylam Pharmaceuticals Inc said its experimental gene-based therapy reduced the level of a disease-causing protein, which leads to a rare organ-damaging hereditary disorder, in an early-stage trial. The therapy was also found to be generally safe and well tolerated, Alnylam said in a statement. Alnylam shares closed at $57.23 on Friday on the Nasdaq.
**BLACKBERRY LTD, $10.66, up 3.4 pct. **COTY INC, $15.56, down 4 pct. **ORBITAL SCIENCES CORP, $21.10, up 5 pct.
**BLACKBERRY LTD, $10.61, up 2.8 pct. **KYTHERA BIOPHARMACEUTICALS INC, $42.00, up 25 pct. Over 1,000 patients from the United States and Canada were enrolled in two late-stage studies for evaluating the drug against a placebo, Kythera said.
**KYTHERA BIOPHARMACEUTICALS INC, $42.00, up 25 pct. **REPROS THERAPEUTICS INC, $26.75, up 26 pct. **REGADO BIOSCIENCES INC, $9.11, up 20 pct.
**KYTHERA BIOPHARMACEUTICALS INC, $42.00, up 25 pct. **AGENUS INC $3.46, up 26 pct. **HUNTSMAN CORP, $20.21, up 6 pct.
**MICROSOFT CORP, Monday close $32.80, up 2 pct premarket. The new share repurchase program, which has no expiration date, replaces a $40 billion buyback program that was set to expire on Sept. 30. **KYTHERA BIOPHARMACEUTICALS INC, Monday close $33.53, up 19.4 pct after market.
**KYTHERA BIOPHARMACEUTICALS INC, Monday close $33.53, up 19.4 pct after market. Over 1,000 patients from the United States and Canada were enrolled in two late-stage studies for evaluating the drug against a placebo, Kythera said. **AGENUS INC Monday close $2.74, up 24 pct premarket.
**KYTHERA BIOPHARMACEUTICALS INC, Monday close $33.53, up 19.4 pct after market. **NOKIA, Monday close $6.24, down 1 pct premarket. Nokia has delayed the launch of a large-screen "phablet" device, originally planned for late September, following a deal to sell its handset business and license patents to Microsoft, a source said on Monday.